Replies to post #117097 on Biotech Values

[genisi]

Practically speaking, given the limited SVR benefit for the nulls, I don't think it makes a huge difference whether they are in the label or not. If I were a null responder, I would wait for the next wave of DAAs.

This is obviously a tough question that patients and docs need to consider on a case-by-case basis. If I were a null responder, I'd try to enroll to a clinical trial including at least two DAA agents plus SOC. If that's not possible and I have an advanced histologic disease, I might consider T+SOC.